|
DPY19L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.89126999999845E-05 |
| Normal-vs-Stage3 |
1.6251444634463E-12 |
| Normal-vs-Stage4 |
8.69369999989544E-07 |
| Stage1-vs-Stage2 |
3.430000E-01 |
| Stage1-vs-Stage3 |
9.435200E-01 |
| Stage1-vs-Stage4 |
4.692800E-01 |
| Stage2-vs-Stage3 |
4.099200E-01 |
| Stage2-vs-Stage4 |
2.355800E-01 |
| Stage3-vs-Stage4 |
4.696000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.783100E-04 |
| Normal-vs-Asian |
1.43169999966553E-07 |
| Caucasian-vs-AfricanAmerican |
8.268800E-01 |
| Caucasian-vs-Asian |
9.249000E-01 |
| AfricanAmerican-vs-Asian |
9.060800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.11022302462516E-16 |
| Male-vs-Female |
8.880600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
7.37909999770636E-08 |
| Normal-vs-Age(81-100Yrs) |
3.622000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.963500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.018500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.359000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.720200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.126400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.501600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.613000E-01 |
| Classical-VS-Follicular |
1.64857016926589E-12 |
| Classical-VS-Other |
2.221200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
6.49039999522927E-08 |
| Tall-VS-Other |
1.383210E-01 |
| Tall-VS-Normal |
1.14059994782423E-09 |
| Follicular-VS-Other |
5.349400E-01 |
| Follicular-VS-Normal |
2.610700E-04 |
| Other-VS-Normal |
2.163600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.10479999984692E-07 |
| N0-vs-N1 |
3.139600E-02 |
|
|
